timothy sykes logo

Stock News

Precigen Stock Surges Amid Promising Clinical Trial Outcomes

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 10/18/2025, 12:20 pm ET 10/18/2025, 12:20 pm ET | 5 min 5 min read
Precigen Stock Surges Amid Promising Clinical Trial Outcomes Thumbnail

Intel Corporation’s stock surged 13.47% as promising FDA designations for Precigen Inc. boosted investor confidence.

Healthcare industry expert:

Analyst sentiment – neutral

Precigen (PGEN) currently holds a challenging market position given its financial fundamentals. The company exhibits significant negative margins: EBIT margin (-3575.6%), EBITDA margin (-3501.1%), and profit margin total (-3573.48%), reflecting substantial operating losses. Revenue figures are also concerning, with a decline of 67.87% over three years and 48.43% over five years. The price-to-sales ratio of 298.49 indicates that market capitalization vastly exceeds its revenue, pointing to overvaluation. Its current ratio of 2.7 provides some short-term liquidity assurance, yet long-term sustainability concerns persist due to the negative book value per share (BVPS) of -0.12 and significant retained earnings deficit.

From a technical analysis standpoint, PGEN’s recent price action indicates a volatile but broadly upward trend. On October 17, the stock closed near its weekly high at $3.96, after experiencing an aggressive upward movement from a low of $3.11 on October 13. This trend suggests bullish momentum supported by a significant volume increase. However, investor caution is advised as a corrective pullback may occur, specifically around the key resistance level of $4.05. An actionable strategy would be to capitalize on pullbacks for entry, with a stop-loss slightly below $3.94 and targeting $4.20 for gains, considering the 5-minute candle formations for timing precision.

Recent favorable news concerning Precigen’s FDA-approved therapy, PAPZIMEOS, which demonstrated a durable response in 83% of patients, provides a promising outlook for the company’s therapeutic segment. The news has positively impacted share prices, as observed with a 6% increase. This therapeutic success positions Precigen competitively within the Biotechnology & Life Sciences benchmarks, potentially bolstering its financial and market performance. However, sustainable operational improvements and strategic debt management are crucial for long-term prospects. Resistance stands at $4.20, while the potential support level is around $3.40. Cautious optimism is warranted, given the positive clinical outcomes and recent share price recovery.

  • The market reacted positively, with shares climbing nearly 6% following the release of these robust clinical results, highlighting investor confidence in the drug’s long-term efficacy.

  • Long-term follow-up data indicates that Precigen’s Papzimeos sustains durable responses, a promising sign for its adoption and future revenue growth.

Candlestick Chart

Weekly Update Oct 13 – Oct 17, 2025: On Saturday, October 18, 2025 Precigen Inc. stock [NASDAQ: PGEN] is trending up by 13.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Precigen’s latest earnings report reflects mixed financial performance, marked by both challenges and potential opportunities. Despite a revenue report of approximately $3.93M, various profitability metrics, such as negative EBIT and gross margins, underscore the company’s financial struggles. The stock’s recent climb to $3.96 on October 17, 2025, indicates a positive market reception to the recent clinical advancements.

More Breaking News

From a broader fiscal standpoint, Precigen maintains a current ratio of 2.7, suggesting ample liquidity to meet its short-term liabilities, though the crushing total liabilities of over $138M remain a concern. The company’s ability to maintain investor interest amid such daunting profitability challenges hinges significantly on breakthroughs like those seen with Papzimeos, underscoring the importance of innovation-driven confidence. Recent financial filings emphasize a strong focus on improving operational efficiencies to sustain momentum gained from recent clinical successes.

Conclusion

Overall, Precigen’s recent clinical achievements, mirrored by positive stock performances, exemplify the market’s endorsement of their innovative therapeutic strategies. With sturdy liquidity and a focus on refining operational execution, the firm appears well-placed to leverage its recent successes into long-term market gains. However, maintaining this momentum will require careful navigation of ongoing financial challenges and strategic capitalization of clinical successes to ensure continued shareholder value creation. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” This advice underscores the necessity for the firm to remain steadfast and methodical in its approach to solidifying its position in an ever-volatile market.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”